In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAFV600E lung adenocarcinoma
Marie‐Julie Nokin(Université de Bordeaux), David Santamarı́a(Centro de Investigación del Cáncer)
Cited by 20
Related Papers
RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade
|Nature Communications|2024|54
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
|Research Square|2023|5